Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby, Peter W., Emberson, Jonathan R., Peto, Leon, Staplin, Natalie, Campbell, Mark, Pessoa-Amorim, Guilherme, Stewart, Richard, Ghosh, Dipansu, Cooke, Graham, Blencowe, Natalie, Moreno-Cuesta, Jeronimo, Desai, Purav, Hine, Paul, Underwood, Jonathan ORCID: https://orcid.org/0000-0001-6963-2821, Easom, Nicholas, Majumdar, Jaydip, Bhagani, Sanjay, Baillie, J Kenneth, Buch, Maya H., Faust, Saul N., Jaki, Thomas, Jeffery, Katie, Juszczak, Edmund, Knight, Marian, Lim, Wei Shen, Montgomery, Alan, Mukherjee, Aparna, Mumford, Andrew, Rowan, Kathryn, Thwaites, Guy, Mafham, Marion, Haynes, Richard, Landray, Martin J., Sandercock, Peter, Darbyshire, Janet, DeMets, David, Fowler, Robert, Lalloo, David, unavvar, Mohammed and Wittes, Janet 2026. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases 26 (1) , pp. 34-45. 10.1016/S1473-3099(25)00361-5

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Background: Sotrovimab is a neutralising monoclonal antibody that has been proposed as a treatment for patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19 pneumonia. In the sotrovimab comparison, eligible and consenting patients were randomly allocated to either usual care alone or usual care plus a single 1g dose of sotrovimab, using web-based unstratified randomisation. Participants were retrospectively categorised according to their baseline serum SARS-CoV-2 nucleocapsid antigen concentration as ‘high-antigen’ or ‘low-antigen’, using the median concentration as a cut-off. The primary outcome was 28-day mortality assessed by intention to treat. Secondary outcomes were time to discharge alive from hospital, and, among those not on invasive ventilation at baseline, progression to invasive ventilation or death. Recruitment closed on 31 March 2024 when funding ended. ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). Findings: From 4 January 2022 to 19 March 2024, 1723 patients were recruited to the sotrovimab comparison. 720 (42%) were classified as high-antigen, 717 (42%) as low-antigen, and 286 (17%) had unknown antigen status. Over 80% of patients were vaccinated, over 80% had anti-spike antibodies at randomisation, and almost all were infected with Omicron variants. In the prespecified primary efficacy population of high-antigen patients, 82/355 (23%) allocated sotrovimab versus 106/365 (29%) allocated usual care died within 28 days (rate ratio 0.75; 95% CI 0.56-0.99; p=0.046). In an analysis of all randomised patients (regardless of antigen status), 177/828 (21%) allocated sotrovimab versus 201/895 (22%) allocated usual care died within 28 days (rate ratio 0.95; 95% CI 0.77-1.16; p=0.60). Interpretation: In patients hospitalised with COVID-19, sotrovimab was associated with reduced mortality in the primary analysis population of patients with a high serum SARS-CoV-2 antigen concentration at baseline, but not in the overall population.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Elsevier
ISSN:	1473-3099
Date of First Compliant Deposit:	13 August 2025
Date of Acceptance:	30 May 2025
Last Modified:	03 Feb 2026 15:22
URI:	https://orca.cardiff.ac.uk/id/eprint/178606

Actions (repository staff only)

Edit Item